FRANKLIN, Tenn. — October 13, 2026 — Verici Dx, (AIM: VRCI), a developer of advanced clinical diagnostics, with an accredited clinical laboratory offering integrated multi-omics services, will showcase its innovative approach to personalized kidney transplant care at ASN Kidney Week 2026, taking place October 21–25 at the Colorado Convention Center in Denver, Colorado.
At Booth 251, Verici Dx will highlight its portfolio of predictive diagnostics designed to provide clinicians with actionable insights at critical points across the kidney transplant journey. The company will feature Tutivia®, its blood-based laboratory developed test (LDT) that delivers predictive, data-driven intelligence in the form of an easy-to-interpret risk score classifying patients as low or high risk of acute rejection of the kidney transplant. By detecting rejection-associated biological mechanisms, the test provides clinicians with a proactive indicator of rejection risk, enabling more precise patient management and risk stratification, better-timed interventions, and the potential to reduce avoidable biopsies and graft loss.
With Tutivia® now authorized for use in all 50 states following recent approval from the New York State Department of Health, Verici Dx is focused on expanding access to predictive transplant diagnostics that can help clinicians make more informed decisions about patient management.
“Kidney transplant medicine is entering an era in which we have the opportunity to make treatment decisions increasingly informed by the biology of each individual patient,” said Sara Barrington, CEO of Verici Dx. “Clinicians need better tools to help determine how aggressively to manage immunosuppression and when additional intervention may be warranted. Tutivia® is designed to provide actionable insight into a patient’s risk of acute rejection, supporting more informed clinical decision-making.”
At ASN Kidney Week, Verici Dx will also highlight the broader potential of its transcriptomic and machine-learning-based approach to develop predictive tests across the transplant continuum, including tools designed to support decision-making before and after transplantation.
About Verici Dx
Verici Dx plc (AIM: VRCI) is a precision diagnostics company focused on supporting clinical management for improving outcomes in transplant patients. The company develops and commercializes advanced clinical laboratory assays by leveraging multi-omics approaches and proprietary machine learning derived algorithms to deliver actionable insights for improved patient management and clinical decision-making. Verici Dx’s lead product, Tutivia®, is a post-kidney transplant test focused on early risk assessment for acute rejection. Testing services are provided at the Company’s CAP accredited/CLIA-certified laboratory in Franklin, TN.
In addition to its transplant diagnostics portfolio, Verici Dx provides multi-omics services to support research, biomarker discovery, and algorithm development for external partners and to support internal initiatives. For more information, please visit https://vericidx.com/ and follow us on LinkedIn.
Media Relations
Christine Quern
cq@christinequern.com
617-650-8497
